Skip to main content

Recent News

COVID Test Antibody

Weak Vaccine Responses in ANCA-Associated Vasculitis Patients

MedPage Today
Jan 18, 2022

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

Read Article
ASK CUSH ANYTHING! Have a Rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/LAC6XrYEyN https://t.co/POGHk7Ibq2
Dr. John Cush @RheumNow (  View Tweet)
Jan 18, 2022
FDA has approved 2 JAK inhibitors for use in severe atopic dermatitis (eczema) - Abbvies upadacitinib (Rinvoq) and Pfizers abrocitinib (Cibinqo). https://t.co/WpCehmB7Vz https://t.co/qKoqV08Z86

Dr. John Cush @RheumNow (  View Tweet)

Jan 18, 2022
J Rheum reports rheums may not be adequately screening for HBV, HCV when using tofacitinib & tocilizumab, despite rec's from CDC, AASLD, PI (but not ACR) to do so. TCZ & TOFA had partial screening (45% & 50%) or no screening (26% & 26%) https://t.co/y28kSJ1JgA

Dr. John Cush @RheumNow (  View Tweet)

Jan 18, 2022
Lupus metanalysis of 41 studies, 17,270 pts shows that REMISSION was maintaned for 1 year in 42–88% of pts, and 5 yrs in 21–70%. Remission assoc w/ older age @dx, lower Dz activity, NO major organ involve. REM had less damage, better QOL https://t.co/1zPcITcYMo

Dr. John Cush @RheumNow (  View Tweet)

Jan 18, 2022
gout target T2T

Does T2T Lead to Fewer Gout Flares?

Jan 17, 2022

Lancet Rheumatology reports that a treat-to-target (T2T) goal of average serum urate less than 6 mg/dL is associated with an absence of gout flares and a reduction in the number of flares in the next 12 months.

Read Article
hip.fx2_.jpg

Fracture Risk with Osteoporosis Drug Holidays

Jan 17, 2022

While bisphosphonate drug holidays are recommended, there are few comparative studies. Annals of Internal Medicine describes a propensity matched comparison study of risedronate and alendronate, showing that, compared to alendronate, risedronate drug holidays were associated with a small increase in risk for hip fractures.  

Read Article
COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients  https://t.co/dzDuza09JW https://t.co/HqL7nWdaP0
Dr. John Cush @RheumNow (  View Tweet)
Jan 17, 2022
Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit!https://t.co/c7oLLCllM8 https://t.co/EGCGFilnVv
Dr. John Cush @RheumNow (  View Tweet)
Jan 17, 2022
World Health Organization has recommended baricitinib & sotrovimab for COVID-19 (both already given EUA by the FDA). BARI (+/- steroids) given as 4 mg qd to severe hospitalized COVID. Sotrovimab, is for outpt, less severe disease. https://t.co/Hv8YdWUoYk https://t.co/l98zcyfGRk https://t.co/RAHKhqPWjp
Dr. John Cush @RheumNow (  View Tweet)
Jan 17, 2022
JAMA reports that between Dec 2020 and July 2021, COVID-19 vaccination saved nearly 241,000 lives, prevented 1, 133, 617 hospitalizations and prevented more than 14 million COVID-19 cases (all in 1st 6 mos of the COVID vaccines) https://t.co/VIcwcPwbjn

Dr. John Cush @RheumNow (  View Tweet)

Jan 17, 2022
Infliximab treatment of RMD/IMIDs by targeting drug levels (therapeutic drug monitoring) was superior to usual care in study with more sustained Dz control without worsening in 458 IMID pts Rx for 52 weeks (TDM 74% vs 70% standard Rx) https://t.co/Ef4b1fYwkw

Dr. John Cush @RheumNow (  View Tweet)

Jan 17, 2022
ICYMI: Why Are Physicians Silent About Outrageous Drug Prices? https://t.co/VMEMLod8EP https://t.co/O6l5eLfFxo
Dr. John Cush @RheumNow (  View Tweet)
Jan 16, 2022
New podcast! Dr. Cush reviews the news and journal articles from the past week on RheumNow. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogrens.https://t.co/A2Kw7rtei6 https://t.co/U6tdmUkP73 https://t.co/Opo5cYc8UB
Dr. John Cush @RheumNow (  View Tweet)
Jan 16, 2022
ICYMI: JAMA study shows that, compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia (HR 0.83; 95% CI, 0.67-1.02; P = .08). https://t.co/72P5EHwD8l

Dr. John Cush @RheumNow (  View Tweet)

Jan 16, 2022
ICYMI: Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.https://t.co/o2b1kwZ9QG https://t.co/ayaDlpl7DI
Dr. John Cush @RheumNow (  View Tweet)
Jan 15, 2022
ICYMI: Patients on biologics are NOT at higher risk for COVID-19 infx. Retrospective matched cohort study compared 7631 Biologic Rx pts to 74910 matched cohort with equal Infx & death rates. COVID infx assoc w/ age, minorities, more comorbidities https://t.co/lY1MVpBoF1

Dr. John Cush @RheumNow (  View Tweet)

Jan 15, 2022
ICYMI: Duloxetine added to usual analgesics failed to improve pain in 132 hip or knee OA pts by WOMAC pain scores: 1) Dulox + usual care vs 2) Usual care showed no diff in pain at 3 mos or 12 mos. https://t.co/2luWWDYP81 https://t.co/KAmqlnofVv
Dr. John Cush @RheumNow (  View Tweet)
Jan 15, 2022
New podcast! Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogrens.https://t.co/Pg4snhCZyo https://t.co/ruzRs0ypcn https://t.co/zwI8baPEcn
Dr. John Cush @RheumNow (  View Tweet)
Jan 15, 2022
Why Are Physicians Silent About Outrageous Drug Prices? https://t.co/hLrUFCiKwm https://t.co/ZgRoW9Duo6
Dr. John Cush @RheumNow (  View Tweet)
Jan 14, 2022
×